| Genomic strategy for targeting therapy in castration-resistant prostate cancer P Mendiratta, E Mostaghel, J Guinney, AK Tewari, A Porrello, WT Barry, ... Journal of clinical oncology 27 (12), 2022-2029, 2009 | 143 | 2009 |
| Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire A Tarhini, Y Lin, H Lin, Z Rahman, P Vallabhaneni, P Mendiratta, ... Journal for immunotherapy of cancer 6, 1-10, 2018 | 60 | 2018 |
| HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer M Alyamani, H Emamekhoo, S Park, J Taylor, N Almassi, S Upadhyay, ... The Journal of clinical investigation 128 (8), 3333-3340, 2018 | 52 | 2018 |
| Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma J Retseck, A Nasr, Y Lin, H Lin, P Mendiratta, LH Butterfield, AA Tarhini Journal of Translational Medicine 16, 1-11, 2018 | 51 | 2018 |
| The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma PC Barata, AG De Liano, P Mendiratta, V Crolley, B Szabados, L Morrison, ... British Journal of Cancer 119 (2), 160-163, 2018 | 50 | 2018 |
| Emerging biomarkers and targeted therapies in urothelial carcinoma P Mendiratta, P Grivas Annals of Translational Medicine 6 (12), 2018 | 34 | 2018 |
| ATM/RB1 mutations predict shorter overall survival in urothelial cancer M Yin, P Grivas, H Emamekhoo, P Mendiratta, S Ali, JA Hsu, M Vasekar, ... Oncotarget 9 (24), 16891, 2018 | 34 | 2018 |
| Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate … PC Barata, M Cooney, P Mendiratta, R Gupta, R Dreicer, JA Garcia Investigational new drugs 37, 331-337, 2019 | 26 | 2019 |
| Effect of switching systemic treatment after stereotactic radiosurgery for oligoprogressive, metastatic renal cell carcinoma PC Barata, P Mendiratta, R Kotecha, D Gopalakrishnan, A Juloori, ... Clinical Genitourinary Cancer 16 (5), 413-419. e1, 2018 | 22 | 2018 |
| Current standard and investigational approaches to the management of hormone-refractory prostate cancer P Mendiratta, AJ Armstrong, DJ George Reviews in urology 9 (Suppl 1), S9, 2007 | 20 | 2007 |
| Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review K Patell, M Kurian, JA Garcia, P Mendiratta, PC Barata, AY Jia, DE Spratt, ... Expert Review of Anticancer Therapy 23 (7), 731-744, 2023 | 18 | 2023 |
| Emerging immunotherapy in advanced renal cell carcinoma P Mendiratta, BI Rini, MC Ornstein Urologic Oncology: Seminars and Original Investigations 35 (12), 687-693, 2017 | 18 | 2017 |
| Atezolizumab in metastatic urothelial carcinoma outside clinical trials: focus on efficacy, safety, and response to subsequent therapies PC Barata, D Gopalakrishnan, VS Koshkin, P Mendiratta, M Karafa, ... Targeted Oncology 13, 353-361, 2018 | 17 | 2018 |
| Treatment selection for men with metastatic prostate cancer who progress on upfront chemo‐hormonal therapy P Barata, H Emamekhoo, P Mendiratta, V Koshkin, A Tyler, M Ornstein, ... The Prostate 78 (13), 1035-1041, 2018 | 15 | 2018 |
| Targeted next-generation sequencing in men with metastatic prostate cancer: a pilot study PC Barata, P Mendiratta, B Heald, S Klek, P Grivas, DPS Sohal, JA Garcia Targeted oncology 13, 495-500, 2018 | 15 | 2018 |
| Biosimilar strategic implementation at a large health system I Kar, M Kronz, E Kolychev, P Silverman, P Mendiratta, BKN Tomlinson, ... American Journal of Health-System Pharmacy 79 (4), 268-275, 2022 | 13 | 2022 |
| Oxford American handbook of oncology GH Lyman Oxford University Press, 2015 | 10 | 2015 |
| Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens. PC Barata, A Gomez de Liano, P Mendiratta, V Crolley, B Szabados, ... Journal of Clinical Oncology 36 (6_suppl), 613-613, 2018 | 9 | 2018 |
| Genomic signatures associated with the development, progression, and outcome of prostate cancer P Mendiratta, PG Febbo Molecular Diagnosis & Therapy 11, 345-354, 2007 | 9 | 2007 |
| Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study PC Barata, M Cooney, P Mendiratta, A Tyler, R Dreicer, JA Garcia Investigational new drugs 36, 1085-1092, 2018 | 6 | 2018 |
